FDA report details problems at plant involved in eye drop recall; European Union drug pricing proposal generates pushback

Taking stock of the drug industry, from the lab to the medicine chest

March 31, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

LOIC VENANCE/AFP/Getty Images STAT+ | FDA report details problems at Global Pharma plant involved in eye drop recall The FDA inspection occurred shortly after Global Pharma Healthcare recalled two different brands of eye drops over contamination concerns. By Ed Silverman STAT+ | European Union drug pricing proposal for the pandemic treaty generates pushback The European Union suggested middle-income countries could pay tiered pricing for drugs and vaccines needed during a pandemic. By Ed Silverman STAT+ | Inflation caused a sizable drop in net drug prices in late 2022, analysis finds After considering inflation, net prices fell 8.5%, compared, which was the largest quarterly decline in real terms seen by the analysts. By Ed Silverman Adobe STAT+ | Opinion: 3 keys to successful biopharma-academia drug development collaborations Many sponsored research collaborations that hope to tap into academia fail. But there are ways to make them work. By Dave Greenwald STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser